Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.
Predicting risk of coronary heart disease (CHD) will always be prone to error. At best, risk factor analysis can predict about 70% of premature CHD. Serum cholesterol alone is not enough. It is more informative to incorporate multiple risk factors into a model of risk analysis (such as the Sheffield or New Zealand tables) than to count risk factors, which in turn is more informative than use of a predetermined cholesterol concentration as a target. The Sheffield and New Zealand tables are based on the Framingham risk function. Hag et at.
have compared four different risk functions: the Framingham (USA), PROCAM (German), Dundee (UK) and British Regional Heart Study (UK) risk functions, to assess the validity of the Framingham function in a European context. These functions were applied to 206 male patients attending the Sheffield Hypertension Clinic. Bland & Altman difference plots were used to compare methods. Although the authors claim good agreement amongst the Framingham, PROCAM and Dundee functions, close inspection shows that the difference between the Framingham and PROCAM estimates increases markedly above a mean CHD risk of 4% and the Framingham and Dundee estimates also show marked differences at higher risks. The authors appear to dismiss the British Regional Heart Study (BRHS) function because its estimate of risk was four-fold lower than for the Framingham function yet the BRHS function was able to predict 60% of CHD in its original publication compared with only 40% in the original Dundee study. Further, the PROCAM, BRHS and Dundee studies were confined to middle-aged men (i.e., no women). Risk analysis is a tricky business. We should use these functions and tables only if we are aware of their limitations. 1999; 36: 397-399 Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. Pfeffer MA, Sacks FM, Moye LA, East C, Goldman S, Nash DT. J Am Coli Cardiol 1999; 33: 125-30 The Cholesterol and Recurrent Events (CARE) trial was a randomized, placebo-controlled trial that tested the effecti veness of pravastatin on the incidence of coronary heart disease events in a broad group of survivors of acute myocardial infarction who had serum total cholesterol concentration <6 mmollL. The primary end-point of the trial was death from a cardiac event or non-fatal myocardial infarction and the trial demonstrated overall benefit. As a result, the British Hyperlipidaemia Association and other interested societies have produced a consensus document urging aggressive management of lipids in postinfarct patients. They advocate a low-density lipoprotein (LDL)-cholesterol target of <3 mmol/L. Pfeffer et at. have now re-interpreted the data from the CARE trial in order to assess the influence of baseline serum lipid concentrations on the effectiveness of pravastatin. They divided patients into quartiles of cholesterol and triglyceride concentrations and demonstrated a significant association between baseline LDL-cholesterol concentration and the primary end-point (fatal cardiac event or non-fatal myocardial infarction) but the difference between the placebo-and pravastatin-treated groups is not significant below a LDL-cholesterol concentration of 3.4 mmol/L. Further, although the risk for a coronary event was not affected by baseline serum triglyceride concentration, the ability of pravastatin to decrease risk falls as serum triglyceride concentration increases and appears not to be significant at serum triglyceride concentrations >6 mmol/L, though the authors do not comment on this.
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Pfeffer et al. also applied Scandinavian
Simvastatin Survival Study ('4S') criteria to their cohort and divided volunteers up into those who were eligible or ineligible. Those who were eligible (serum cholesterol concentration >5.5 mmol/L) demonstrated a significant reduction in coronary death or non-fatal myocardial infarction whereas those who were not eligible (serum cholesterol <5.5 mmol/L) did not. They conclude that patients in the CARE trial with low serum LDL-cholesterol concentrations do not obtain clinical benefit with lipid-lowering medication, and suggest that other risk factors must be involved in the development of myocardial infarction, and that these factors should form the focus for new investigative efforts. In the meantime, the consensus statement from the British Hyperlipidaemia Association will influence physicians to prescribe pills to achieve very low serum LDL-cholesterol concentrations for no proven clinical benefit (below LDL-cholesterol of 3.4 mmol/L), aI-Antitrypsin is an important protease inhibitor with many genetic variants that are inherited codominantiy. The three most common alleles in European populations are M, Sand Z, the latter two giving rise to a I-antitrypsin deficiency. Homozygotes for the Z allele have serum concentrations of at-antitrypsin which are 10-20% of normal, and an increased risk of developing emphysema or liver disease. Individuals who are SZ heterozygotes have serum aI-antitrypsin concentrations approximately 40% of normal, but (unlike ZZ homozygotes) it is less certain whether these individuals are at increased risk of lung disease.
In an attempt to clarify the situation, the authors studied 94 individuals who were SZ heterozygotes. Twenty-eight were index cases identified on clinical grounds and, in an attempt to avoid ascertainment bias, 66 were non-index cases identified by family studies. The mean follow-up time was 6 years (standard deviation 4 years). The index and non-index cases were similar with respect to age, sex and follow-up time but differed in smoking history and forced expiratory volume (FEY I). The Standardized Mortality Ratio for the index cases was 4.3 [95% confidence interval (CI): 1.9 -8.5], and for the non-index cases was 0.8 (95% CI: 0.3 -1.8). Eight index cases died during the study at a mean age of 65 years, six (75%) from pulmonary emphysema and one (12.5%) from pulmonary fibrosis. This compared to the deaths of five nonindex cases at a mean age of 77 years, two (40%) of which were from emphysema and two (40%) from pneumonia. Spirometry results indicated that the mean FEY I of the index cases was 59% of the predicted value, compared with 94% for the nonindex cases. The authors conclude, based on their findings for the non-index cases, that only a small fraction of SZ heterozygotes are at risk of developing emphysema, and they do so at an older age than ZZ homozygotes.
Unfortunately, the paper does not seem to have answered the question of whether SZ heterozygotes are ipso facto at increased risk of lung disease. As the authors themselves suggest, a larger study involving population screening with two decades of follow-up is required, which would eliminate selection bias but would be difficult to set up. Meanwhile, of the 13 SZ heterozygotes who died during the study, II (85%) died from lung disease of one form or another, which is a higher proportion than in the general population. The jury is still out. If you want to add another layer of complexity to your understanding of growth hormone (GH) release, this review of growth hormone secretagogues (GHS) is a good place to start. These synthetic compounds were developed from the opioids to release GH in vivo, the first success being GHreleasing hexapeptide (GHRP-6). In the mid 1990s it was found that the GHS act through different receptors to those for GHRH. They are thus artificial ligands for a receptor whose endogenous ligand is as yet unknown. A number of GHS have now been developed which act on the pituitary, not only through different receptors but also through different intracellular signalling pathways to GHRH and possibly on different sornatotrope populations. There is some evidence that the hypothalamus may be the main site of action. In vivo, GHS and GHRH show synergistic action on GH release. Although the endogenous ligand has not been identified, the GHS hold out promise as useful diagnostic tools (fewer side effects than insulininduced hypoglycaemia) and as therapeutic agents in GH deficiency. Studies in adults have suggested the existence of functional adrenal insufficiency (AI) in adults and its possible haemodynamic effects. Controversy exists as to the benefits of high-dose steroids in sepsis, and the potential benefits of steroids for functional AI have yet to be defined. This study investigated the incidence of adrenal insufficiency in 33 children with septic shock admitted to the Paediatric Intensive Care Unit (lCU) at Guy's Hospital, London. Using a post-Synacthen cortisol increment of <200 nmol/L as their diagnostic criterion, they found the incidence of AI was 52%. Median calculated risk of mortality for age was 17% in AI and 7% in those with adequate adrenal function (AF) (P=0.032) but mortality was similar (P= I). Children with AI were more likely to require inotropes (P=0.023) and had a longer median time to resolution of shock (P=0.008) but had no difference in median duration of ventilation (P =0.94) or ICU stay (P =0.56). Whilst the implications of this study are relevant, I am uneasy with the criteria for the diagnosis of AI. Baseline cortisol concentrations were in the range 30-3264 nmol/L (median 1018, n= 17) in AI and 637--4553 nmol/L (median 1083, n=16) in AF. Using 'conventional' post-Synacthen criteria of peak cortisol concentration <500 nmol/L plus an increment <200 nmol/L, only 12% showed AI. The authors acknowledge that a population of more than 500 patients would be required to determine whether supplementary steroids reduce mortality in such children if their response criterion was used. However, the definition of AI in children is contro-
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versial and before undertaking such work the definition of adrenal insufficiency used should be reconsidered and the impact on study design reviewed. This excellent review introduces a new journal from the Royal Society of Chemistry. Two of the authors are members of the Editorial Board and are leading authorities in exposure assessment and biological monitoring. The term 'reactivity determinants' refers to features associated with the element such as the ionic and covalent bonding tendencies, particle size and shapes, formation of complexes and radical formation. Also included are physical state and atomic properties -ion size, oxidation state etc. In addition, the discussion focuses on important biological determinants, e.g., bioavailability, compartmentalization, half-life, tolerance and susceptibility. Each determinant (21 are included) is helpfully defined and its influence on the behaviour of elements in biological systems is discussed, with special reference to toxicological responses. Although this informative review is concerned with elements, the principles elaborated are equally relevant to organic agents. Even those who usually experience an adverse reaction when it comes to inorganic chemistry should not be worried about exposure to this particular article.
